ArticlePediatric research2026
Bovine colostrum as a human milk fortifier for very preterm infants with slow feeding advancement: a randomized controlled trial.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Narrative review of human milk fortifiers for preterm infants.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFortification of human milk for very preterm infants (VPIs) with alternatives to conventional bovine milk-based fortifiers remains minimally studied. This trial tested whether fortification with protein-rich bovine colostrum (BC) improves feeding intolerance and clinical variables in VPIs receiving enteral nutrition with a relatively slow advancement.
methodsIn this unblinded, two-centre, randomised, controlled trial (FortiColos CN), VPIs (gestational age, 26 + 0 to 31 + 6 weeks) were fed human milk fortified with BC (n = 74) or a conventional fortifier (CF, FM85, Nestlé, n = 72) for at least two weeks, starting when enteral feeding volume reached 80-100 mL/kg body weight/d. Incidence of feeding intolerance, nutrition intake, body growth, morbidities and clinical biochemical parameters were compared between the two groups.
resultsNo statistically significant difference was found in the incidence of feeding intolerance or in most of the nutritional or body growth parameters (p > 0.05). All recorded morbidity incidences and haematological and blood biochemical parameters were also similar between groups. Amino acids (Phe, Pro, Ser, Tyr, Val) showed higher levels in the infants receiving BC.
conclusionsBC appeared safe when used as a fortifier to human milk for VPIs with slow feeding advancement, but did not improve feeding tolerance or clinical variables. IMPACT: Fortifying human milk with bovine colostrum (BC) in very preterm infants (VPIs) is safe but did not improve feeding tolerance, growth or clinical outcomes, compared with a conventional fortifier (CF), when used during slow enteral feeding advancement. This study adds to the limited clinical evidence on the use of BC as a human milk fortifier in VPIs receiving enteral feeding with different feeding protocols. The findings support the safety of BC as a human milk fortifier in VPIs but suggest limited short-term clinical benefits over currently used fortifiers.
Identifiers
41554861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.